Year: 2026 | Month: April-June | Volume: 11 | Issue: 2 | Pages: 153-160
DOI: https://doi.org/10.52403/ijshr.20260219
A Comparative Study to Evaluate the Effect of Vilanterol/Fluticasone Furoate Versus Formoterol/Fluticasone Propionate in Bronchial Asthma Patients
Garima Verma1, Arpita Singh2, Ajay Kumar Verma3, Hemant Kumar4, Pooja Shukla5, Atul Jain6, Punit Kanaujia7
1Senior Resident, Department of Pharmacology, Dr. RMLIMS, Lucknow
2Professor & HOD, Department of Pharmacology, Dr. RMLIMS, Lucknow
3Professor & HOD, Department of Respiratory Medicine, Dr. RMLIMS, Lucknow
4Additional Professor, Department of Respiratory Medicine, Dr. RMLIMS, Lucknow
5Additional Professor, Department of Pharmacology, Dr. RMLIMS, Lucknow
6Professor, Department of Pharmacology, MMCMSR, Sadopur, Ambala
7Senior Resident, Department of Pharmacology, Dr. RMLIMS, Lucknow
Corresponding Author: Dr. Arpita Singh
ABSTRACT
Background: Bronchial asthma is a chronic inflammatory airway disease affecting millions worldwide, especially children and adolescents. Inhaled Corticosteroids (ICS) and Long- Acting Beta-agonists (LABAs) are the cornerstone of treatment. Vilanterol/ Fluticasone Furoate (VI/FF), a once-daily LABA/ICS combination, offers improved adherence, better lung function, and enhanced symptom control compared to traditional twice-daily regimens like Formoterol/Fluticasone Propionate (FM/FP)
Aims: To compare the effect of Vilanterol and Fluticasone Furoate versus Formoterol and Fluticasone Propionate combination on pulmonary functions in patients with bronchial asthma
Methods: A prospective study was conducted over 18 months involving 92 asthma patients divided equally into two groups: VI/FF and FM/FP. Patients were assessed after 6 months of treatment for spirometric parameters (FEV₁ and FVC) and adherence using the ASK-12 questionnaire.
Results: Both groups showed significant improvements in FEV₁ and FVC over 6 months, with VI/FF demonstrating a more significant improvement in FEV1(p=0.001) and FVC (p =0.011). The adherence scores were better in the VI/FF group, particularly regarding inconvenience/forgetfulness and behaviour.
Conclusion: VI/FF showed superior improvement in lung function and better adherence compared to FM/FP. Once-daily dosing with VI/FF enhances convenience, making it a potentially preferred treatment for bronchial asthma.
Keywords: Bronchial asthma, Inhaled Corticosteroids (ICS), Long-Acting Beta-agonists (LABAs), Pulmonary function test